Intermediate Risk NMIBC BCG Naïve Treatment of Choice with Dr. Leonard G. Gomella, MD, FACS
Автор: Grand Rounds in Urology
Загружено: 2025-05-02
Просмотров: 357
Leonard G. Gomella, MD, FACS, explores bladder cancer treatment, particularly in the context of intermediate-risk, BCG-naïve disease.
In this 23-minute presentation, Dr. Gomella reviews the significant advancements in bladder cancer treatment options. He highlights the AUA and NCCN guidelines for intermediate-risk disease, emphasizing the role of BCG as a primary treatment. The BCG shortage has driven the use of alternative intravesical therapies such as gemcitabine, mitomycin, and gemcitabine-docetaxel, which are increasingly recognized as viable options.
Experts attending IBCU join the conversation, addressing challenges in clinical trial design, including ethical concerns over trial access to BCG when it is otherwise unavailable. The discussion also examines the growing role of biomarker-driven treatment selection and the heterogeneity of intermediate-risk disease, which necessitates refined patient stratification.
Future directions include ongoing trials evaluating new agents, novel drug delivery mechanisms, and potential radiation therapy approaches. The Bridge trial and other ongoing studies may further define the role of gemcitabine-docetaxel as a primary alternative to BCG, shaping the future standard of care for bladder cancer.
Don't forget to join the GRU Community: https://grandroundsinurology.com/regi...
Follow us on Twitter/X: https://x.com/GRUrology
And like and subscribe to us here on YouTube!
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
